Last Updated: May 10, 2026

List of Excipients in Branded Drug IBUPROFEN 200


✉ Email this page to a colleague

« Back to Dashboard


Exipient Strategy and Commercial Opportunities for Ibuprofen 200 mg

Last updated: March 1, 2026

Ibuprofen 200 mg is a commonly prescribed nonsteroidal anti-inflammatory drug (NSAID) used to reduce pain, fever, and inflammation. Its popularity derives from its efficacy, safety profile, and widespread OTC availability. The excipient formulation significantly impacts product stability, bioavailability, manufacturing, shelf life, and patient compliance.

What Are the Key Excipients in Ibuprofen 200 mg Formulations?

  • Binders: Microcrystalline cellulose (MCC) is predominant, providing tablet integrity.
  • Disintegrants: Crospovidone or croscarmellose facilitate rapid disintegration.
  • Lubricants: Magnesium stearate ensures smooth tablet manufacturing and ejection.
  • Glidants: Colloidal silica improves powder flow.
  • Fillers/Diluents: Lactose monohydrate is common, offering compressibility and stability.
  • Coatings: Film coatings made from hydroxypropyl methylcellulose (HPMC) or polyvinyl alcohol improve taste masking and stability.

Strategic Considerations in Exipient Selection

Optimization for Bioavailability and Stability

  • Use of disintegrants that promote rapid dissolution enhances onset of action.
  • Lactose as filler offers good compressibility but may cause issues in lactose-intolerant patients.
  • Film coatings can extend shelf life and mask unpleasant taste, improving patient compliance.

Compatibility and Regulatory Compliance

  • Excipients must be compatible with ibuprofen and other formulation components.
  • They must meet regulatory standards (e.g., FDA, EMA) for purity, safety, and batch-to-batch reproducibility.

Manufacturing Efficiency

  • Excipients like MCC and magnesium stearate facilitate high-speed production.
  • Selection of excipients that reduce manufacturing defects lowers costs and enhances yields.

Patent and Market Differentiation

  • Innovative excipient blends or proprietary coatings can differentiate products.
  • Patents around specific excipient combinations can extend exclusivity.

Commercial Opportunities in Exipient Development

Enhanced Formulations

  • Fast-dissolving tablets: Use of superdisintegrants improves absorption and onset.
  • Chewable tablets: Alternative excipients like mannitol for better palatability.
  • Immediate-release vs. modified-release: Coatings or matrix systems to control release.

Specialty Excipients

  • Use of plant-based or organic excipients appeals to certain market segments.
  • Biodegradable or plant-derived film coatings align with consumer preferences.

Differentiation through Novel Excipients

  • Polymers with targeted release profiles.
  • Coatings that improve stability under challenging storage conditions.

Global Market Expansion

  • Formulations tailored to regulatory requirements in emerging markets.
  • Incorporation of excipients suitable for hot, humid climates to improve stability.

Market Outlook and Competitive Positioning

  • The global ibuprofen market was valued at over USD 5 billion in 2021 (Grand View Research, 2022).
  • The OTC segment dominates, with a growing demand for formulations with improved taste and onset.
  • Excipients enabling rapid dissolution, taste masking, and stability have become focal points for innovation.

Regulatory Landscape and Considerations

  • Excipients must adhere to pharmacopeial standards and be approved in target markets.
  • Changes in excipient sources or grades require stability and bioavailability testing.
  • Regulatory agencies scrutinize excipients that impact safety, especially in pediatric formulations.

Key Takeaways

  • Selecting appropriate excipients influences product performance, shelf life, and patient adherence.
  • Innovation in excipient usage—and coating technology—presents pathways for market differentiation.
  • Cost, regulatory compliance, and manufacturing robustness govern formulation decisions.
  • There is an ongoing demand for formulations with improved onset, stability, and taste masking.
  • Global expansion hinges on tailoring excipient profiles to regional regulatory and climatic conditions.

FAQs

What is the most common excipient in ibuprofen 200 mg tablets?

Microcrystalline cellulose (MCC) is most commonly used as a binder and filler, providing tablet strength and stability.

How do excipients influence ibuprofen bioavailability?

Disintegrants like croscellose promote rapid tablet breakup, facilitating faster release and absorption. Coatings can also modulate drug release profiles.

Are there opportunities for allergen-free excipients in ibuprofen formulations?

Yes. Using non-lactose fill-ins and plant-based coatings caters to lactose intolerance and vegan preferences.

What excipient innovations can extend the shelf life of ibuprofen tablets?

Polymer coatings resistant to moisture and oxygen can enhance stability under varying storage conditions.

How do regional regulatory differences affect excipient choices?

Regulations vary regarding permissible excipients and purity standards. Formulators must customize excipient profiles accordingly.


References

[1] Grand View Research. (2022). Ibuprofen Market Size, Share & Trends Analysis Report.
[2] U.S. Food and Drug Administration. (2022). Excipients in approved drug products.
[3] EMA. (2020). Guideline on excipients in the label and leaflet of medicinal products for human use.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.